Observational studyPediatric nephrology (Berlin, Germany)2026
Pegcetacoplan in idiopathic and familial pediatric C3 glomerulopathy.
Observational study in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complement diagnostics and therapeutics for the pediatric population: early successes and opportunities for further advancement.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundC3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) represent a continuous spectrum of a glomerular disease driven by dysregulation of the complement and characterized by C3 deposition alone or associated with immunoglobulins. Despite the significant burden and poor prognosis associated with these conditions, no therapies have been approved for their treatment in children.
methodsIn this observational study, we present three pediatric cases that span the clinical and pathogenic spectrum of C3G/IC-MPGN, including multi-resistant nephrotic syndrome with clear terminal pathway activation, familial genetic C3G with early anti-C3 intervention, and multi-resistant nephrotic syndrome of unclear etiology, likely related to IC.
resultsAll three patients were successfully treated with the C3/C3b inhibitor pegcetacoplan, that inhibited C3, blocked C3 consumption, and restored physiological C3 levels, leading to significant proteinuria reduction within the first month. After six months, patients experienced notable improvements in kidney function, a complete remission of nephrotic syndrome, and normalized proteinuria levels. There were no treatment-related adverse events, only mild infections that resolved with standard oral therapy.
conclusionsThese findings support the potential of C3 inhibition with pegcetacoplan in pediatric patients with refractory or genetic C3G.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.